Select Language
PD-L1
PD-L1 Overview
| English Name | Programmed death-ligand 1 | Approved Drugs | 12 |
| Drugs in Clinical Trials | 172 | Target Synonym | HPD-L1，Programmed Cell Death 1 Ligand 1，PDCD1L1，B7H1，PDL1，Programmed Death Ligand 1，B7-H1，B7-H，B7-H1 Antigen，CD274，B7 homolog 1，PDCD1 ligand 1，PD-L1，PDCD1LG1，CD274 Molecule，CD274 Antigen |
| Highest Development Stage | Approved | ||
| English Name | Programmed death-ligand 1 |
| Target Synonym | HPD-L1，Programmed Cell Death 1 Ligand 1，PDCD1L1，B7H1，PDL1，Programmed Death Ligand 1，B7-H1，B7-H，B7-H1 Antigen，CD274，B7 homolog 1，PDCD1 ligand 1，PD-L1，PDCD1LG1，CD274 Molecule，CD274 Antigen |
| Approved Drugs | 12 |
| Drugs in Clinical Trials | 172 |
| Highest Development Stage | Approved |
PD-L1 Product List
- Product Category
Protein (27)Kits (2)Cell (4)Antibody (1)
- Product Status
Launched (34)
- Species
Human (19)Cynomolgus / Rhesus macaque (4)Mouse (6)Rabbit (2)Canine (2)Feline (1)
- Tag
His Tag (8)Fc Tag (5)Strep Tag (1)His Tag & Fc Tag & Avi Tag (1)Mouse IgG Fc Tag (2)Fc Tag & Avi Tag (3)His Tag & Avi Tag (4)Llama IgG Fc Tag (1)Mouse IgG Fc Tag & Avi Tag (1)- (7)Tag Free (1)
- Conjugate
Unconjugated (18)Biotin-labeled (9)- (6)PE Labeled (1)
Total: 34
- 1
- 2
- 3
- 4
PD-L1 Background
Programmed cell death 1 ligand 1 (PDL1) is also known as B7-H, B7H1, MGC142294, MGC142296, PD-L1, PDCD1L1 and PDCD1LG1,which is a member of the growing B7 family of immune molecules and is involved in the regulation of cellular and humoral immune responses.PDL1 is a cell surface immunoglobulin superfamily with two Ig-like domains within the extracellular region and a short cytoplasmic domain. This protein is broadly expressed in the majority of peripheral tissues as well as hematopoietic cells. Interaction between PDL1 and its receptors belonging to the CD28 family of molecules provide both stimulatory and inhibitory signals in regulating T cell activation and tolerance. PDL1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression.
PD-L1 Synonyms
PD-L1,CD274,B7-H1,PDCD1L1,PDCD1LG1
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Bintrafusp alfa | M-7824; GSK-4045154; MSB-0011359C | Phase 3 Clinical | Merck Serono | Anus Neoplasms; Biliary Tract Neoplasms; Brain metastases; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Colonic Neoplasms; Colorectal Neoplasms; Esthesioneuroblastoma, Olfactory; Gallbladder Neoplasms; Ganglioglioma; Head and Neck Neoplasms; Hematologic Neoplasms; Intestinal Neoplasms; Lung Neoplasms; Lymphoma; Melanoma; Metastatic breast cancer; Microsatellite Instability; Nasopharyngeal Carcinoma; Neoplasm Metastasis; Neoplasms; Neoplasms, Germ Cell and Embryonal; Nose Neoplasms; Oropharyngeal Neoplasms; Pancreatic Neoplasms; Papillomavirus Infections; Penile Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Rectal Neoplasms; Respiratory papillomatosis; Sarcoma; Sarcoma, Kaposi; Skin Melanoma; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Thymic epithelial tumor; Thymoma; Thymus Neoplasms; Triple Negative Breast Neop | Details |
| Erfonrilimab | KN-046 | Phase 3 Clinical | Jiangsu Alphamab Biopharmaceuticals Co Ltd | Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colonic Neoplasms; Colorectal Neoplasms; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Gastrointestinal Neoplasms; Lymphoma; Neuroendocrine Tumors; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms; Thymoma; Thymus Neoplasms; Triple Negative Breast Neoplasms | Details |
| HLX-43 | HLX-43; HLX43 | Phase 3 Clinical | Shanghai Henlius Biotech Inc | Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colonic Neoplasms; Colorectal Neoplasms; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Gastroesophageal Junction Neoplasms; Head and Neck Neoplasms; Liver Neoplasms; Lung Neoplasms; Nasopharyngeal Carcinoma; Ovarian Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms | Details |
| LB-1410 | LB-1410 | Phase 3 Clinical | L&L Biopharma Co Ltd | Lymphoma; Neoplasms; Solid tumours; Uterine Cervical Neoplasms | Details |
| SGN-PDL1V | SGN-PDL1V; PF-08046054 | Phase 3 Clinical | Seagen Inc | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Esophageal Squamous Cell Carcinoma; Pancreatic Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms | Details |
| SHS-006(Nanjing Sanhome Pharmaceutical) | SHS-006; SH-006; SH006 | Phase 3 Clinical | Nanjing Sanhome Pharmaceutical Co Ltd | Carcinoma, Hepatocellular; Liver Neoplasms; Solid tumours | Details |
| CA-170 | CA-170; AUPM-170 | Phase 3 Clinical | Aurigene | Carcinoma, Non-Small-Cell Lung; Neoplasms; Solid tumours | Details |
| Sotiburafusp alfa | HB0025; HB-0025 | Phase 3 Clinical | HuaBo Biopharm Co Ltd, Shanghai Huaota Biopharmaceutical Co Ltd, Zhejiang Huahai Pharmaceutical Co Ltd | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Hematologic Neoplasms; Kidney Neoplasms; Solid tumours; Triple Negative Breast Neoplasms | Details |
| HL-301 | HL-301 | Phase 3 Clinical | Hanmi Pharmaceutical Co Ltd | Acute Bronchitis; Lung Neoplasms; Pulmonary Disease, Chronic Obstructive; Radiation Pneumonitis | Details |
| Pumitamig | PM-8002; BMS-986545; PM8002; BNT-327 | Phase 3 Clinical | Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal adenocarcinoma; Gastroesophageal Junction Neoplasms; Glioblastoma; Glioma; Liver Neoplasms; Lung Neoplasms; Mesothelioma; Metastatic breast cancer; Neoplasms; Neuroendocrine Tumors; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms | Details | |
| FAZ-053 | FAZ-053; LAE-005; LAE005 | Phase 2 Clinical | Novartis Pharma Ag | Chordoma; Sarcoma, Alveolar Soft Part; Solid tumours; Triple Negative Breast Neoplasms | Details |
| MAX-10181 | MAX-1; MAX-10181; MX-10181 | Phase 2 Clinical | MaxiNovel Pharmaceuticals Co Ltd | Glioblastoma; Glioma; Neoplasms; Solid tumours | Details |
| 89Zr-DFO-Atezolizumab | 89Zr-DFO-Atezolizumab | Phase 2 Clinical | University of Texas Southwestern Medical Center | Carcinoma, Renal Cell; Diagnostic agents; Lymphoma, B-Cell | Details |
| PD-L1 t-haNK cell therapy | Phase 2 Clinical | Nantkwest Inc | Esophageal Neoplasms; Glioblastoma; Head and Neck Neoplasms; Neoplasm Metastasis; Pancreatic Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms | Details | |
| RC-98 | RC-98; RC98; RC98-ADC | Phase 2 Clinical | Solid tumours; Stomach Neoplasms | Details | |
| Durvalumab/Gefitinib | Phase 2 Clinical | Medimmune | Carcinoma, Non-Small-Cell Lung | Details | |
| Vudalimab | XmAb-717; XmAb-20717; XmAb 717 | Phase 2 Clinical | Xencor Inc | Adenocarcinoma, Clear Cell; Adenoma, Acidophil; Adnexal Diseases; Astrocytoma; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Hepatocellular; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Castration-Sensitive Prostate Neoplasms; Cholangiocarcinoma; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Gastroesophageal Junction Neoplasms; Hodgkin Disease; Melanoma; Mesothelioma; Nasopharyngeal Carcinoma; Ovarian Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Rectal Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Thymoma; Thyroid Neoplasms; Uterine Cervical Neoplasms; Vulvar Neoplasms | Details |
| Cadapersen | RG-6084; RO-7191863 | Phase 2 Clinical | F. Hoffmann-La Roche Ltd | Hepatitis B; Hepatitis B, Chronic | Details |
| BMS-936559 | MDX-1105; BMS-936559 | Phase 2 Clinical | Bristol-Myers Squibb Company | Colonic Neoplasms; Colorectal Neoplasms; HIV Infections; Hodgkin Disease; Leukemia, Myelogenous, Chronic; Liver Neoplasms; Lymphoma, Non-Hodgkin; Melanoma; Multiple Myeloma; Neoplasms; Rectal Neoplasms; Sepsis; Shock, Septic; Small Cell Lung Carcinoma | Details |
| PD-L1/CTLA4 bispecific monoclonal antibody (Changhai Hospital) | Phase 2 Clinical | Changhai Hospital of Navy Medical University | Pancreatic Neoplasms | Details | |
| PM-8001 | 6MW3111; PM-8001 | Phase 2 Clinical | Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Neoplasms; Solid tumours | Details | |
| Betifisolimab | MSB-2311 | Phase 2 Clinical | Suzhou Transcenta Therapeutics Co Ltd | Solid tumours | Details |
| Evixapodlin | GS-4224; OX-4224 | Phase 2 Clinical | Gilead Sciences Inc | Carcinoma, Non-Small-Cell Lung; Solid tumours | Details |
| 89Zr-durvalumab | Phase 2 Clinical | Radboud University Nijmegen | Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms | Details | |
| Danburstotug | STI-3031; STI-A1015; IMC-001 | Phase 2 Clinical | Sorrento Therapeutics Inc | Biliary Tract Neoplasms; Lymphoma; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell, Peripheral; Neoplasm Metastasis; Neoplasms; Solid tumours | Details |
| Type 1 diabetes stem cell gene therapy (Altheia Science) | Phase 2 Clinical | Altheia Science Srl | Diabetes Mellitus, Type 1 | Details | |
| Recombinant humanized PD-L1 monoclonal antibody (Taizhou Houde Aoke Technology) | LP-002 | Phase 2 Clinical | Taizhou Houde Aoke Technology Co Ltd | Carcinoma, Squamous Cell; Digestive System Neoplasms; Melanoma; Primary mediastinal B cell lymphoma; Small Cell Lung Carcinoma; Solid tumours | Details |
| AP-203 | AP-203; AP203 | Phase 2 Clinical | AP Biosciences Inc | Carcinoma, Non-Small-Cell Lung; Esophageal Squamous Cell Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| HB-0036 | HB-0036 | Phase 2 Clinical | HuaBo Biopharm Co Ltd | Carcinoma, Non-Small-Cell Lung; Solid tumours | Details |
| SKB-103 | SKB103; SKB-103 | Phase 2 Clinical | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | Solid tumours | Details |
| [18F]AlF-NOTA-PCP2 | 18F-AlF-NOTA-PCP2 | Phase 2 Clinical | Shandong First Medical University | Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Glioblastoma; Squamous Cell Carcinoma of Head and Neck | Details |
| HY-05350 | HY-0005; HY-05350 | Phase 2 Clinical | Sichuan Huiyu Seacross Pharma Technology Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Mesothelioma; Ovarian Neoplasms; Pancreatic Neoplasms; Solid tumours | Details |
| IBI-3014 | IBI3014; IBI-3014 | Phase 2 Clinical | Solid tumours | Details | |
| DB-1419 | DB-1419 | Phase 2 Clinical | Duality Biologics (Suzhou) Co Ltd | Solid tumours | Details |
| CVL006 | CVL006; B006 | Phase 2 Clinical | Convalife (Shanghai) Co Ltd | Neoplasms; Solid tumours | Details |
| SOA-101 | SOA-101; SOA101 | Phase 2 Clinical | Shine-On BioMedical Co Ltd | Brain Neoplasms; Breast Neoplasms; Lung Neoplasms; Mouth Neoplasms; Ovarian Neoplasms; Solid tumours | Details |
| JSKN-033 | JSKN033; JSKN-033; JSKN-003/Envafolimab | Phase 2 Clinical | Jiangsu Alphamab Biopharmaceuticals Co Ltd | Carcinoma, Non-Small-Cell Lung; Neoplasms; Solid tumours; Uterine Cervical Neoplasms | Details |
| SPX-303 | SPX-303 | Phase 2 Clinical | SparX Biopharmaceutical Corp | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Gastroesophageal Junction Neoplasms; Melanoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms | Details |
| MAX-80391 | MAX-80391; MAX-8 | Phase 2 Clinical | MaxiNovel Pharmaceuticals Co Ltd | Solid tumours | Details |
| PRS-344 | PRS-344S095012; S-095012; S-95012; PRS-344/ONC0055; PRS-344; PRS-344/S095012 | Phase 2 Clinical | Pieris Pharmaceuticals Inc | Solid tumours | Details |
| Pacmilimab | CX-072 | Phase 2 Clinical | Cytomx Therapeutics Inc | Breast Neoplasms; Lymphoma; Melanoma; Neoplasms; Solid tumours; Triple Negative Breast Neoplasms | Details |
| BPB-101 | BPB-101 | Phase 2 Clinical | Betta Pharmaceuticals Co Ltd | Solid tumours | Details |
| LB-101 (Centessa Pharmaceuticals) | LB-101 (Centessa Pharmaceuticals); LB-101 Tetravalent PD-L1xCD47 LockBody bispecific monoclonal antibody | Phase 2 Clinical | Centessa Pharmaceuticals Plc | Solid tumours | Details |
| HK-010 | HK-010; HK010 | Phase 2 Clinical | Anhui Anke Biotechnology (Group) Co Ltd, Hefei Hankemab Biotechnology Co Ltd | Neoplasms; Solid tumours | Details |
| AB-001 (Agastiya Biotech) | AB01 (Agastiya Biotech); AB001 (Agastiya Biotech); AB-01 (Agastiya Biotech) | Phase 2 Clinical | Agastiya Biotech LLC | Neoplasms | Details |
| 6MW-3511 | 6MW-3511 | Phase 2 Clinical | Mabwell (Shanghai) Bioscience Co Ltd | Neoplasms; Solid tumours | Details |
| 18F-BMS-986229 | 18F-BMS-986229; [18F]BMS-986229 | Phase 2 Clinical | Bristol-Myers Squibb International Corp, PeptiDream Inc | Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Stomach Neoplasms | Details |
| AP-505 | AP-505; B1962; AP505 | Phase 2 Clinical | AP Biosciences Inc | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Colorectal Neoplasms; Liver Neoplasms; Lung Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms | Details |
| Emfizatamab | GNC-038 | Phase 2 Clinical | Sichuan Baili Pharmaceutical Co Ltd, SystImmune | Arthritis, Rheumatoid; Central Nervous System Lymphoma; Lupus Erythematosus, Systemic; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Solid tumours | Details |
| 99mTc-NM-01 | 99mTc-NM-01 | Phase 2 Clinical | Nanomab Technology Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| HB-0028 | HB-0028 | Phase 2 Clinical | HuaBo Biopharm Co Ltd, Shanghai Huaota Biopharmaceutical Co Ltd | Solid tumours; Uterine Cervical Neoplasms | Details |
| PM-1022 | PM-1022 | Phase 2 Clinical | Neoplasms | Details | |
| DR-30206 | DR-30206 | Phase 2 Clinical | Zhejiang Doer Biologics Corp | Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| 706-3SBio | SSGJ-706; 706 anti -PD1/PD -L1 BsAb; 706 anti-PD1/PD-L1 Bispecific antibody | Phase 2 Clinical | 3sbio Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Composite Lymphoma; Digestive System Neoplasms; Esophageal Neoplasms; Lymphoma; Neoplasms; Solid tumours | Details |
| BCD-106 | BCD-106 | Phase 2 Clinical | BIOCAD JSC | Solid tumours | Details |
| BAT-7104 | BAT-7104 | Phase 2 Clinical | Bio-Thera Solutions Ltd | Neoplasms; Solid tumours | Details |
| Opamtistomig | LBL-024; LBL024 | Phase 2 Clinical | Nanjing Leadsbiolabs Co Ltd | Carcinoma, Neuroendocrine; Melanoma; Neoplasms; Ovarian Neoplasms; Solid tumours; Triple Negative Breast Neoplasms | Details |
| IBC-0966 | IBC-0966 | Phase 2 Clinical | Neoplasms | Details | |
| QLF31907 | QLF31907; QLF-31907 | Phase 2 Clinical | Qilu Pharmaceutical Co Ltd | Carcinoma, Transitional Cell; Lymphoma, Non-Hodgkin; Melanoma; Neoplasms; Solid tumours | Details |
| INCB-099280 | INCB-099280; INCB-99280 | Phase 2 Clinical | Incyte Corp Ltd | Carcinoma, Hepatocellular; Carcinoma, Merkel Cell; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Melanoma; Mesothelioma; Microsatellite instability-high cancer; Mismatch Repair Deficient Cancer; Nasopharyngeal Carcinoma; Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Uterine Cervical Neoplasms | Details |
| FH-2001 | FH-2001 | Phase 2 Clinical | Solid tumours | Details | |
| Nebratamig | GNC-035 | Phase 2 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Breast Neoplasms; Hematologic Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Metastatic breast cancer; Solid tumours | Details |
| Carrizumab | Phase 2 Clinical | Jiangsu Hengrui Medicine Co Ltd | Adenocarcinoma; Esophageal Neoplasms; Stomach Neoplasms | Details | |
| Recombinant anti-PD-L1/TGF-β bispecific antibody | Y101D; Y-101D | Phase 2 Clinical | Wuhan Yzy Biopharma Co Ltd | Carcinoma, Hepatocellular; Pancreatic Neoplasms; Solid tumours | Details |
| 6MW-3211 | 6MW3211; 6MW-3211 | Phase 2 Clinical | Mabwell (Shanghai) Bioscience Co Ltd | Carcinoma, Renal Cell; Leukemia, Myeloid, Acute; Lung Neoplasms; Lymphoma; Myelodysplastic Syndromes; Neoplasms | Details |
| Q-1802 | Q-1802 | Phase 2 Clinical | Qure Biotechnology (Shanghai) Co Ltd | Esophageal Neoplasms; Gastrointestinal Neoplasms; Solid tumours | Details |
| HLX-301 | HLX-301 | Phase 2 Clinical | Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Lymphoma; Neoplasm Metastasis; Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details | |
| PD-L1 antibody combined with CTLA-4 antibody (Shanghai Zhongshan Hospital) | Phase 2 Clinical | Shanghai Zhongshan Hospital | Cholangiocarcinoma | Details | |
| Palverafusp alfa | IMM-2510; SYN-2510; AXN-2510 | Phase 2 Clinical | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Esophageal Squamous Cell Carcinoma; Neoplasms; Sarcoma; Solid tumours; Triple Negative Breast Neoplasms | Details | |
| PM-1003 | PM1003 | Phase 2 Clinical | Solid tumours | Details | |
| PM-8003 | PM8003 | Phase 2 Clinical | Solid tumours | Details | |
| ABSK-043 | ABSK043 | Phase 2 Clinical | ABbisko Therapeutics Co Ltd | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Esophageal Neoplasms; Neoplasms; Sarcoma; Solid tumours | Details |
| Lesabelimab | BC-003; ADG-104 | Phase 2 Clinical | Adagene (Suzhou) Ltd, Baifan Biotechnology (Shanghai) Co Ltd, Dragonboat Biopharmaceutical, Guilin Sanjin Pharmaceutical Co Ltd | Carcinoma, Renal Cell; Neoplasms; Penile Neoplasms; Urinary Bladder Neoplasms | Details |
| Emdifen | Phase 1 Clinical | Chinese Academy Of Medical Sciences, Tianjin Chase Sun Pharmaceutical Co Ltd | Solid tumours | Details | |
| Chimeric antigen receptor T-cell therapy (Hunan Zhaotai Yongren Biotech) | Z-CTLs | Phase 1 Clinical | Hunan Zhaotai Yongren Biotech Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| Lodapolimab | LY-3300054 | Phase 1 Clinical | Eli Lilly And Company | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Microsatellite instability-high cancer; Neoplasms; Pancreatic Neoplasms; Skin Melanoma; Solid tumours; Triple Negative Breast Neoplasms | Details |
| SL-279252 | TAK-252; SL-279252 | Phase 1 Clinical | Shattuck Labs Inc, Takeda Pharmaceutical Co Ltd | Adenocarcinoma; Astrocytoma; Carcinoma, Basosquamous; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Melanoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms | Details |
| LOR-S03 | CDX-527 | Phase 1 Clinical | Celldex Therapeutics | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Neoplasms; Fallopian Tube Neoplasms; Head and Neck Neoplasms; Liver Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| MCLA-145 | MCLA-145 | Phase 1 Clinical | Incyte Corp, Merus Nv | Lymphoma, B-Cell; Neoplasms; Solid tumours | Details |
| INCB-086550 | INCB-086550; INCB-86550 | Phase 1 Clinical | Incyte Corp | Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Melanoma; Solid tumours | Details |
| Opucolimab | HLX-20 | Phase 1 Clinical | Neoplasms; Solid tumours | Details | |
| IMMH-010 | IMMH-010 | Phase 1 Clinical | Tianjin Chase Sun Pharmaceutical Co Ltd | Neoplasms; Solid tumours | Details |
| Simridarlimab | IBI-322; IBI322 | Phase 1 Clinical | Bone Marrow Neoplasms; Hematologic Neoplasms; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, T-Cell; Neoplasms; Solid tumours | Details | |
| dual anti-HER2/anti-PD-L1 CAR T-cell therapy (Sichuan University) | Phase 1 Clinical | Sichuan University | Carcinoma, Non-Small-Cell Lung; Metastatic breast cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Stomach Neoplasms | Details | |
| anti-PD-L1 CSR T-cell therapy (Marino Biotechnology) | Phase 1 Clinical | Beijing Marino Biotechnology Co Ltd | Glioblastoma; Neoplasms | Details | |
| anti-PSMA/anti-PSCA CAR T-cell therapy PD-1 silent (Shanghai Unicar-Therapy Bio-medicine) | Phase 1 Clinical | Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd | Hormone-Resistant Prostate Neoplasms | Details | |
| AB-101 (Arbutus Biopharma) | AB-101 (Arbutus Biopharma) | Phase 1 Clinical | Arbutus Biopharma Corp | Hepatitis B; Hepatitis B, Chronic | Details |
| SIM-0237 | SIM-0237; SIM-237 | Phase 1 Clinical | Simcere Pharmaceutical Group Ltd | Solid tumours; Urinary Bladder Neoplasms | Details |
| LP-008 | LP-008 | Phase 1 Clinical | Lepu Biopharma Co Ltd | Solid tumours | Details |
| AN-8025 | AN-8025 | Phase 1 Clinical | Hangzhou Adlai Nortye Biopharma Co Ltd | Solid tumours | Details |
| EMB-09 | EMB-09 | Phase 1 Clinical | Shanghai Epimab Biotherapeutics, Inc | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Hepatitis B, Chronic; Melanoma; Nasopharyngeal Carcinoma; Neoplasms; Ovarian Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms | Details |
| CYTO-102 | CYTO-NK-102; CYTO-102; COH06 | Phase 1 Clinical | CytoImmune Therapeutics Inc | Carcinoma, Non-Small-Cell Lung; Lung Neoplasms | Details |
| TS-1905 | TS-1905; LY-01019; BA-1201 | Phase 1 Clinical | Shandong Boan Biotechnology Co Ltd | Solid tumours | Details |
| BH-3120 | BH-3120 | Phase 1 Clinical | Hanmi Pharmaceutical Co Ltd | Solid tumours | Details |
| Xirestomig | ATG-101; ATG101; YN051 | Phase 1 Clinical | The Origin Cell Technology Group Co Ltd | Hematologic Neoplasms; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Solid tumours | Details |
| QL-301 | QL-301 | Phase 1 Clinical | Qlsf Biotherapeutics Inc | Neoplasms | Details |
| HLX-37 | HLX37; HLX-37 | Phase 1 Clinical | Shanghai Henlius Biotech Inc | Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Neoplasm Metastasis; Solid tumours; Triple Negative Breast Neoplasms | Details |
| Q-1801 | Q-1801; Q 1801 | Phase 1 Clinical | Qure Biotechnology (Shanghai) Co Ltd | Solid tumours | Details |
| PEC-QT | PEC-QT; VCTX-210 | Phase 1 Clinical | Crispr Therapeutics Ag, Viacyte Inc | Autoimmune Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 1; Endocrine System Diseases; Glucose Metabolism Disorders; Immune System Diseases; Metabolic Diseases | Details |
| IMGS-001 | IMGS-001 | Phase 1 Clinical | The University Of Texas MD Anderson Cancer Center | Colorectal Neoplasms; Neoplasms; Prostatic Neoplasms; Solid tumours; Triple Negative Breast Neoplasms | Details |
| ABL-501 | ABL-501 | Phase 1 Clinical | Abl Bio Inc | Solid tumours | Details |
| CTX-8371 | CTX-8371 | Phase 1 Clinical | Compass Therapeutics LLC | Carcinoma, Non-Small-Cell Lung; Hodgkin Disease; Melanoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms | Details |
| IBC-Ab002 | IBC-Ab002 | Phase 1 Clinical | ImmunoBrain Checkpoint Inc | Alzheimer Disease | Details |
| Pd-1-pik | Pd-1-pik | Phase 1 Clinical | Huashan Hospital Affiliated To Fudan University | Glioblastoma | Details |
| Reozalimab | IBI-318; LY-3434172; LY3434172 | Phase 1 Clinical | Eli Lilly And Company | Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Lymphoma, Extranodal NK-T-Cell; Neoplasms; Small Cell Lung Carcinoma | Details |
| VSV-02 | VSV-02 | Phase 1 Clinical | Joint Biosciences Ltd | Breast Neoplasms; Lung Neoplasms; Melanoma; Neoplasms; Solid tumours | Details |
| 188Re-NM-01 | 188Re-NM-01 | Phase 1 Clinical | Nanomab Technology Ltd | Lung Neoplasms | Details |
| 68Ga-NOTA-WL12 | Phase 1 Clinical | Beijing Cancer Hospital | Carcinoma, Non-Small-Cell Lung | Details | |
| [18F]DK222 | [18F]DK-222; [18F]DK222 | Phase 1 Clinical | Sidney Kimmel Comprehensive Cancer Center | Carcinoma; Carcinoma, Non-Small-Cell Lung | Details |
| JSKN-027 | JSKN027; JSKN-027 | Phase 1 Clinical | Alphamab Oncology | Neoplasms; Solid tumours | Details |
| PF-08046037 | PF-08046037; SGN-PDL1iT | Phase 1 Clinical | Pfizer Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Melanoma; Neoplasms; Squamous Cell Carcinoma of Head and Neck | Details |
| BMS-986238 | BMS-986238 | Phase 1 Clinical | Bristol-Myers Squibb Belgium Sa | Lymphoma; Solid tumours | Details |
| Naptumomab estafenatox/Durvalumab | NTX-352 | Phase 1 Clinical | Neotx Therapeutics Ltd | Solid tumours | Details |
| DCR-PDL1 | DCR-PDL1 | Phase 1 Clinical | Dicerna Pharmaceuticals Inc | Solid tumours | Details |
| XB-628 | XB628 | Phase 1 Clinical | Exelixis Inc | Neoplasms; Solid tumours | Details |
| BHP-01 | BHP-01; BHP01; α-PD-L1/4-1BB DLL3 CAR-T | Phase 1 Clinical | Chengdu Brilliant Pharmaceutical Co Ltd | Small Cell Lung Carcinoma | Details |
| JSKN-022 | JSKN022; JSKN-022 | Phase 1 Clinical | Alphamab Oncology | Neoplasms; Solid tumours | Details |
| LW-347 | LW-347 | Phase 1 Clinical | Shanghai Longwood Biopharmaceuticals Co Ltd | Neoplasms | Details |
| A-337 (Klus Pharma) | A337 (Klus Pharma); A-337 (Klus Pharma) | Phase 1 Clinical | Klus Pharma Inc | Neoplasms | Details |
| PMI-06 | PMI-06; PMI06; 18F-DK222; [18F]DK-222 | Phase 1 Clinical | Precision Molecular Inc | Carcinoma, Non-Small-Cell Lung | Details |
| YL-222 | YL222; YL-222 | Phase 1 Clinical | MediLink Therapeutics Co Ltd | Solid tumours | Details |
| BAT-7205 | BAT7205; BAT-7205 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Neoplasm Metastasis; Solid tumours | Details |
| SM-2275 | SM-2275; SM2275 | Phase 1 Clinical | Zhuhai StarMab BioMed Technology Ltd | Solid tumours | Details |
| ND-021 | ND-021; NM21-1480; CS-2006; CS2006 | Phase 1 Clinical | Cstone Pharmaceuticals, Numab Therapeutics Ag | Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Squamous Cell; Colorectal Neoplasms; Fallopian Tube Neoplasms; Neoplasms; Peritoneal Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms | Details |
| MAX-001 | MAX-001; MAX001 | Phase 1 Clinical | Inflamax Pharmaceuticals (Guangzhou) Co Ltd | Solid tumours | Details |
| KM602 | KM602; KM-602; XZP-KM602 | Phase 1 Clinical | Xuanzhu (Shijiazhuang) Biotechnology Co Ltd | Solid tumours | Details |
| B-901 | B-901; B901 | Phase 1 Clinical | FutureGen Biopharm (Beijing) Co Ltd | Solid tumours | Details |
| Recombinant anti-PD-L1/TGF-β bifunctional fusion protein | Phase 1 Clinical | Hualan Genetic Engineering (Henan) Co Ltd | Solid tumours | Details | |
| AUR-106 | AUR-106 | Phase 1 Clinical | Aurigene Discovery Technologies Ltd | Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Colonic Neoplasms; Esophageal Neoplasms; Kidney Neoplasms; Neoplasms; Stomach Neoplasms | Details |
| 177Lu-RAD204 | 177Lu-anti-PD-L1 sdAb; RAD-204; 177Lu-RAD204 | Phase 1 Clinical | Radiopharm Theranostics Ltd | Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Mismatch Repair Deficient Cancer; Skin Melanoma; Small Cell Lung Carcinoma; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms | Details |
| RAD-203 | RAD-203 | Phase 1 Clinical | Radiopharm Theranostics Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| Dual-targeting VEGFR1 and PD-L1 CAR-T cells Therapy (Sichuan University) | Phase 1 Clinical | Sichuan University | Ascites; Serositis | Details | |
| Ori-Bs-001 | Ori-Bs-001 | Phase 1 Clinical | OriCell Therapeutics Co Ltd | Solid tumours | Details |
| HBM-9027 | HBM-9027; HBM9027 | Phase 1 Clinical | Harbour Biomed | Neoplasms; Solid tumours | Details |
| HS-10386 | HS-10386 | Phase 1 Clinical | Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Hansoh Biomedical Co Ltd | Solid tumours | Details |
| QL-415 | QL-415 | Phase 1 Clinical | Qlsf Biotherapeutics Inc | Neoplasms | Details |
| ASC-61 | ASC-61 | Phase 1 Clinical | Ascletis Pharma Inc | Neoplasms; Solid tumours | Details |
| BPI-371153 | BPI-371153 | Phase 1 Clinical | Betta Pharmaceuticals Co Ltd | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Lymphoma; Solid tumours | Details |
| CS-23546 | CS-23546; CS23546 | Phase 1 Clinical | Shenzhen Chipscreen Biosciences Co Ltd | Immune System Diseases; Neoplasms | Details |
| SG-1408 | SG-1408; SG1408 | Phase 1 Clinical | Hangzhou Shangjian Biotechnology Co Ltd | Solid tumours | Details |
| CHECKvacc | CF33-hNIS-antiPDL1 | Phase 1 Clinical | City Of Hope National Medical Center, Imugene Ltd | Breast Neoplasms; Metastatic breast cancer; Triple Negative Breast Neoplasms | Details |
| Gallium [68Ga] Natan recombinant PD-L1 single domain antibody | SNA-002; 68Ga-NOTA-SNA002 | Phase 1 Clinical | Smartnuclide Biopharma | Contrast agents; Neoplasms; Solid tumours | Details |
| SHS-009 | SHS-009; SH009; SH-009 | Phase 1 Clinical | Nanjing Sanhome Pharmaceutical Co Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Liver Neoplasms; Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms | Details |
| CN-202 | CN-202 | Phase 1 Clinical | Curon Biopharmaceutical Ltd | Hematologic Neoplasms; Solid tumours | Details |
| Recombinant oncolytic type II herpes simplex virus (Binhui Biopharmaceutical) | BS-006; oHSV2-BiTEs; oHSV2CD3-PD-L1 | Phase 1 Clinical | Wuhan Binhui Biotechnology Co Ltd | Melanoma; Neoplasms; Solid tumours; Uterine Cervical Neoplasms | Details |
| FS222 mAb² (F-star Therapeutics) | FS-222 | Phase 1 Clinical | F-star Beta Ltd | Neoplasm Metastasis; Neoplasms; Solid tumours | Details |
| IMM-2520 | IMM-2520 | Phase 1 Clinical | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details | |
| TT-00420/Atezolizumab | Phase 1 Clinical | TransThera Sciences (Nanjing) Inc | Gastrointestinal Neoplasms | Details | |
| PF-07257876 | Phase 1 Clinical | Pfizer Inc | Carcinoma, Non-Small-Cell Lung; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck | Details | |
| AN-4005 | AN-4005 | Phase 1 Clinical | Hangzhou Adlai Nortye Biopharma Co Ltd | Lymphoma; Neoplasms; Solid tumours | Details |
| BR-102 | BR102 | Phase 1 Clinical | Zhejiang BioRay Biopharmaceuticals Co Ltd | Neoplasms; Solid tumours | Details |
| TST-005 | TST-005; TST005 | Phase 1 Clinical | Suzhou Transcenta Therapeutics Co Ltd | Neoplasms; Papillomavirus Infections; Solid tumours | Details |
| GS-19 | GT-90008; GS-19; GS-19-PLB-1C | Phase 1 Clinical | Gensun Biopharma Inc | Solid tumours | Details |
| Ragistomig | ABL-503; TJ-L14B/ABL503; ABL503; TJ-L14B | Phase 1 Clinical | I-Mab Biopharma Co Ltd | Solid tumours | Details |
| CCX-559 | CCX-559 | Phase 1 Clinical | Chemocentryx Inc | Neoplasms; Solid tumours | Details |
| Dual-targeting HER2 and PD-L1 CAR-T Cell Therapy (Sichuan University) | Phase 1 Clinical | Sichuan University | Peritoneal Neoplasms; Pleural Effusion, Malignant | Details | |
| QLS31901 | QLS-31901; QLS31901 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Neoplasms | Details |
| IMM2505 | IMM2505; IMM-2505 | Phase 1 Clinical | SunHo (China) BioPharmaceutical Co Ltd | Solid tumours | Details |
| SKB-337 | SKB337; A-337; SKB-337 | Phase 1 Clinical | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | Solid tumours | Details |
| GNC-039 | GNC-039 | Phase 1 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Glioma; Hematologic Neoplasms; Neoplasm Metastasis; Solid tumours | Details |
| IBI-323(Innovent Biologics) | IBI-323 | Phase 1 Clinical | Neoplasms; Solid tumours | Details | |
| BJ-005 | BJ-005 | Phase 1 Clinical | Boji Biomedical Technology (Hangzhou) Co Ltd | Lymphoma; Solid tumours | Details |
| Garivulimab | BGB-A333 | Phase 1 Clinical | BeOne Medicines Ltd | Neoplasms; Solid tumours | Details |
| Recombinant anti-PD-L1 human monoclonal antibody (Jiansu huaiyu) | Phase 1 Clinical | Jiangsu Huaiyu Pharmaceutical Co Ltd | Solid tumours | Details | |
| Durvalumab/Selumetinib sulfate | Phase 1 Clinical | Astrazeneca Plc | Neoplasms | Details | |
| 18F-BMS-986192 | BMS-986192-[18F] | Clinical | Bristol-Myers Squibb Company | Neoplasms | Details |
| 68Ga-THP-APN09 | Clinical | Beijing Cancer Hospital | Lung Neoplasms | Details | |
| [68Ga]Ga-NOTA-RW102 | Clinical | Huashan Hospital | Carcinoma, Non-Small-Cell Lung | Details | |
| 18F-WL12 | 18F-WL12; 18F-WL-12 | Clinical | Beijing Cancer Hospital | Lung Neoplasms | Details |
| 68Ga-WL12 | [68Ga]WL12; 68Ga-WL12; 68Ga-WL-12 | Clinical | Beijing Cancer Hospital | Lung Neoplasms | Details |
| CTB-1 | CTB-1 | Clinical | GTS Biotech LLC | Neoplasms | Details |
| 89Zr-KN035（Wuxi No. 4 People's Hospital） | Clinical | Wuxi No. 4 People | Solid tumours | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Socazolimab | ZKAB001; STI-A1014; STIA-1014; ZKAB-001; STI-1014 | Approved | Sorrento Therapeutics Inc, Zhaoke (Guangzhou) Oncology Pharmaceutical Ltd | 善克钰 | Mainland China | Uterine Cervical Neoplasms | Zhaoke (Guangzhou) Oncology Pharmaceutical Ltd | 2023-12-19 | Bile Duct Neoplasms; Biliary Tract Neoplasms; Carcinoma, Transitional Cell; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Melanoma; Osteosarcoma; Small Cell Lung Carcinoma; Uterine Cervical Neoplasms | Details |
| Envafolimab | KN-035; ASC-22 | Approved | 3d Medicines (Sichuan) Co Ltd, Suzhou Alphamab Co Ltd | ENWEIDA, 恩维达 | Mainland China | Mismatch Repair Deficient Cancer; Microsatellite instability-high cancer | 3d Medicines (Sichuan) Co Ltd | 2021-11-25 | Bile Duct Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colonic Neoplasms; Colorectal Neoplasms; Dermatofibrosarcoma; Endometrial Neoplasms; Esophageal Squamous Cell Carcinoma; Gastroesophageal Junction Neoplasms; Hepatitis B, Chronic; HIV Infections; Liver Neoplasms; Microsatellite instability-high cancer; Mismatch Repair Deficient Cancer; Sarcoma; Sepsis; Shock, Septic; Solid tumours; Stomach Neoplasms | Details |
| Retlirafusp alfa | SHR-1701 | Approved | Jiangsu Hengrui Medicine Co Ltd | 艾泽利 | Mainland China | Stomach Neoplasms; Esophageal Neoplasms | Suzhou Suncadia Biopharmaceuticals Co Ltd | 2026-01-07 | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Hodgkin Disease; Lung Neoplasms; Lymphangioma, Cystic; Nasopharyngeal Carcinoma; Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Rectal Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Uterine Cervical Neoplasms | Details |
| Atezolizumab | RG-7446-42; RO-5541267; 52CMI0WC3Y (UNII code); RG-7446; MPDL-3280A | Approved | Genentech Inc | 泰圣奇, Tecentriq, 泰善可 | United States | Carcinoma, Non-Small-Cell Lung | Genentech Inc | 2016-05-18 | Anus Neoplasms; Bile Duct Neoplasms; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Chondrosarcoma; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Gastroesophageal Junction Neoplasms; Gastrointestinal Neoplasms; Genital Neoplasms, Female; Glioblastoma; Glioma; Head and Neck Neoplasms; Hematologic Neoplasms; Hodgkin Disease; Idiopathic Pulmonary Fibrosis; Kidney Diseases; Kidney Neoplasms; Laryngeal Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Liposarcoma; Liposarcoma, Myxoid; Liver Neoplasms; Lung Neoplasms; Lymphoma; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Lymphoproliferative Disorders; Melanoma; Metastatic breast cancer; Multiple Myeloma; Mycosis Fungoides; Myelodysplastic Syndromes; Neoplasms; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Oropharyngeal Neoplasms; | Details |
| Avelumab | PF-06834635; MSB-0010718C | Approved | Merck Serono | Bavencio | United States | Carcinoma, Merkel Cell | Emd Serono Inc | 2017-03-23 | Adenocarcinoma; Carcinoma; Carcinoma, Adenoid Cystic; Carcinoma, Hepatocellular; Carcinoma, Merkel Cell; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Squamous Cell Carcinoma; Fallopian Tube Neoplasms; Glioblastoma; Gonadal Disorders; Hodgkin Disease; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, B-Cell; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell; Lymphoma, T-Cell, Peripheral; Meningeal Neoplasms; Meningioma; Mesothelioma; Microsatellite Instability; Microsatellite instability-high cancer; Multiple Myeloma; Mycosis Fungoides; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasms; Neoplasms, Germ Cell and Embryonal; Neuroendocrine Tumors; Osteosarcoma; Ovarian Neoplasms; Pancreatic Neoplasms; Papil | Details |
| Tagitanlimab | KL-A167; A-167; HBM-9167 | Approved | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | 科泰莱 | Mainland China | Nasopharyngeal Carcinoma | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | 2024-12-25 | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Hodgkin Disease; Lymphoma; Lymphoma, B-Cell; Lymphoma, Extranodal NK-T-Cell; Nasopharyngeal Carcinoma; Small Cell Lung Carcinoma; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms | Details |
| Adebrelimab | SHR-1316; HTI-1088; HTI-1316 | Approved | Atridia Pty Ltd, Jiangsu Hengrui Medicine Co Ltd | 艾瑞利 | Mainland China | Small Cell Lung Carcinoma | Shanghai Suncadia Medicine Co Ltd | 2023-02-28 | Adenocarcinoma; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Gastroesophageal Junction Neoplasms; Lung Neoplasms; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasms; Ovarian Diseases; Ovarian Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Rectal Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms | Details |
| Durvalumab | 28X28X9-OKV (UNII code); MEDI-4736 | Approved | Medimmune Llc | Imfinzi, 英飞凡 | United States | Carcinoma, Non-Small-Cell Lung | Astrazeneca Uk Ltd | 2017-05-01 | Adenocarcinoma; Adenocarcinoma of Lung; Bile Duct Neoplasms; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Merkel Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal adenocarcinoma; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fallopian Tube Neoplasms; Gallbladder Neoplasms; Gastroesophageal Junction Neoplasms; Glioblastoma; Head and Neck Neoplasms; Hormone-Resistant Prostate Neoplasms; Hydronephrosis; Kidney Neoplasms; Laryngeal Diseases; Laryngopharyngitis; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Liver Neoplasms; Lung Neoplasms; Lymphoma; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peri | Details |
| Cosibelimab | TG-1501; CK-301 | Approved | Dana-Farber Cancer Institute | UNLOXCY, UNLOXCIT, Unloxcyt | United States | Carcinoma, Squamous Cell | Checkpoint Therapeutics Inc | 2024-12-13 | Carcinoma, Merkel Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Endometrial Neoplasms; Head and Neck Neoplasms; Hodgkin Disease; Lung Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin; Melanoma | Details |
| Sugemalimab | CS-1001; WBP-3155 | Approved | Cstone Pharmaceuticals (Suzhou) Co Ltd | 择捷美, Cejemly, ZEJIEMEI | Mainland China | Carcinoma, Non-Small-Cell Lung | Cstone Pharmaceuticals (Suzhou) Co Ltd | 2021-12-20 | Adenocarcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Gastroesophageal Junction Neoplasms; Head and Neck Neoplasms; Hodgkin Disease; Lymphoma; Lymphoma, Extranodal NK-T-Cell; Lymphoma, T-Cell; Melanoma; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms | Details |
| Atezolizumab/Hyaluronidase | Approved | Genentech Inc | TECENTRIQ HYBREZA | United States | Sarcoma, Alveolar Soft Part; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Small Cell Lung Carcinoma | Genentech Inc | 2024-09-12 | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma; Sarcoma, Alveolar Soft Part; Small Cell Lung Carcinoma | Details | |
| Benmelstobart | CBT-502; APL-502; TQ-B2450; TQB2450; TQB-2450 | Approved | Apollomics Inc | 安得卫 | Mainland China | Small Cell Lung Carcinoma | Sino Biopharmaceutical Ltd | 2024-04-30 | Adenocarcinoma; Bile Duct Neoplasms; Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Cholangiocarcinoma; Digestive System Diseases; Digestive System Neoplasms; Endometrial Neoplasms; Esophageal Diseases; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fallopian Tube Neoplasms; Gastrointestinal Diseases; Gastrointestinal Neoplasms; Genital Neoplasms, Female; Hepatitis B, Chronic; Hodgkin Disease; Liver Neoplasms; Lung Neoplasms; Lymphoma; Lymphoma, B-Cell; Lymphoma, Extranodal NK-T-Cell; Melanoma; Nasopharyngeal Carcinoma; Neoplasms; Neoplasms, Squamous Cell; Ovarian Neoplasms; Peritoneal Neoplasms; Primary mediastinal B cell lymphoma; Sarcoma; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms | Details |
Product Reviews
C***z2025-04-30
0People LikeWe are always very satisfied with the reagents ordered from ACRO!- A***n2024-10-18 0People LikeWe order at Acrobiosystems for ELISA/ECL reagents. Up to now, we are happy with their products (quality) and the support they provide to us. It is quick to have a quote and very fast shipment.
- Y***n2023-04-22 0People LikeThe delivery is so fast and so good.we received the package in two days.The products are very good in quality.And the price is reasonable.Those are quality products.We trust them. They are useful in our experiments. The results come from the products are stable and reliable.So if someone wants to get something like this, they can buy the products of the company.You will be not disappointed.They are really good!
Load More
- Overview
- Product List
- Marketed Drug Information
- Product Reviews
- Clinical Drug Information
Share to:
Online Message
Contact Us
BettinastraBe 30, 60325 Frankfurt am Main